GlobalData on MSN8 天
Vir enrols first subject in Phase III programme to assess CHD therapy
The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...
Business Insider1 个月
Strong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market ...
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price target of $6.00. Edward White’s rating is ...